ReviewFrontiers in cell and developmental biology2026
From metabolism to genome integrity: NRF2 as a key mediator of cancer therapy response.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic rewiring in cancer is sustained by deregulated intracellular signaling, frequently due to genetic mutation of oncogenes, tumor suppressors or oncometabolite genes. These mutations strongly affect the activity of Transcription Factors (TFs) and epigenetic remodelling factors, ultimately leading to different metabolic subtypes. Of note, several metabolites have been proposed to significantly modulate gene expression through post-translational modifications of metabolic enzymes, TFs and histones, sustaining the intracellular feedback loop in cancer cells. Among the TFs involved in metabolic reprogramming of cancer cells, NRF2, a well-characterized factor in the oxidative stress response, emerged as a crucial player. NRF2 is at the crossroads of critical intracellular pathways linking metabolism, DNA damage and chromatin remodelling. These findings point to NRF2 as a pivotal player in cancer therapy resistance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.